Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | EYA2 | O00167 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060551 | 0.98 | TDP1 (0.68) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL19726617 | 0.95 | TDP1 (0.67) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL12892856 | 0.95 | TDP1 (0.59) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL5590784 | 0.95 | TDP1 (0.64) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL5551303 | 0.93 | TDP1 (0.68) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL5533656 | 0.93 | TDP1 (0.64) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL16349998 | 0.93 | TDP1 (0.62) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL12392750 | 0.91 | TDP1 (0.67) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL7740566 | 0.91 | TDP1 (0.67) | TDP1BLMPMP22KDM4EALOX15 | |
| SCHEMBL15499760 | 0.88 | TDP1 (0.50) | TDP1BLMPMP22KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115000-B2 | Pyrazine derivatives and uses thereof in renal monitoring | MALLINCKRODT LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110250139-A1 | Modified Pyrazine Derivatives and Uses Thereof | MEDIBEACON, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110250140-A1 | Modified Pyrazine Derivatives and Uses Thereof | MEDIBEACON, INC. | 2011-10-13 | — | — | US | disclosed |
| EP-1836175-B1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-7674902-B2 | Luminescent metal complexes for monitoring renal function | MALLINCKRODT INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2135863-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | MEDIBEACON INC. | 2009-08-06 | — | — | US | disclosed |
| EP-2039688-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080299038-A1 | Luminescent Metal Complexes for Monitoring Renal Function | MALLINCKRODT INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299038-A1 | Luminescent Metal Complexes for Monitoring Renal Function | REN, GLS, ATP6V1B1 | TDP1 3740/4885BLM 2497/4885PMP22 2391/4885 |
| US-20110250139-A1 | Modified Pyrazine Derivatives and Uses Thereof | GLS, GLS2, PLPBP | TDP1 1649/4885BLM 605/4885PMP22 641/4885 |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | TDP1 3171/4885BLM 4190/4885PMP22 1253/4885 |
| US-20110250140-A1 | Modified Pyrazine Derivatives and Uses Thereof | GLS, PKM, PKN3 | TDP1 3593/4885BLM 4283/4885PMP22 199/4885 |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | GLS, CYP3A5, PYCR1 | TDP1 3113/4885BLM 4642/4885PMP22 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.